We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Teva Files Paragraph IV ANDA For Avapro

Law360 (July 20, 2004, 12:00 AM EDT) -- Israeli drug maker Teva Pharmaceuticals has filed an application to make a generic version of Sanofi-Synthelabo’s hypertension drug Avapro.

Teva filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification with the U.S. Food and Drug Administration for the marketing in the U.S.of a generic version of the drug Sanofi-Synthelabo said.

The filing does not challenge Sanofi-Synthelabo’s basic product patent that expires in 2011, but alleges only that the Teva formulation does not infringe the pharmaceutical formulation patent expiring in 2015, Sanofi-Synthelabo said....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.